country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

259 Results for "

C8

" in MedChemExpress (MCE) Product Catalog:

Products (259)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

Fenofibrate

36 Publications Verification

Cat. No.: HY-17356

CAS No.: 49562-28-9

Target:

PPAR Cytochrome P450 Autophagy

Research Areas:

Cardiovascular Disease Cancer

Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Rebastinib

13 Cited Publications

Cat. No.: HY-13024

CAS No.: 1020172-07-9

Purity: 99.91%

Synonyms: DCC-2036

Target:

Bcr-Abl Cytochrome P450 Tie FOXO Src FLT3 Apoptosis

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC₅₀ values of 0.8 nM and 4 nM against Abl1 ^WT and Abl1 ^T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC₅₀ = 0.0533 μM) and CYP2C9 (IC₅₀ = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC₅₀ of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

αvβ1 integrin-IN-1 TFA

7 Cited Publications

Cat. No.: HY-100445A

Purity: 98.28%

Target:

Integrin

Research Areas:

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

αvβ1 integrin-IN-1

7 Cited Publications

Cat. No.: HY-100445

CAS No.: 1689540-62-2

Purity: 99.51%

Target:

Integrin

Research Areas:

Cardiovascular Disease Cancer

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Gemfibrozil

7 Cited Publications

Cat. No.: HY-B0258

CAS No.: 25812-30-0

Synonyms: CI-719

Target:

PPAR Cytochrome P450

Research Areas:

Cardiovascular Disease Metabolic Disease Cancer

Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

Compare